Psoriasiform reactions during treatment with abatacept

Triggering or worsening of psoriasis has been traditionally reported in patients treated with each of the three currently available tumor necrosis factor (TNF)-α blocking agents (infliximab, etanercept and adalimumab). [2],[4],[5] In a meta-analysis of 13 relevant trials, four of 1332 RA patients w...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of dermatology, venereology, and leprology venereology, and leprology, 2014-01, Vol.80 (1), p.92
Main Authors: Conde-Montero, Elena, Baniandrés-Rodríguez, Ofelia, Mendoza-Cembranos, María Dolores, Horcajada-Reales, Celia, Suárez-Fernández, Ricardo
Format: Article
Language:English
Subjects:
Abatacept
Abatacept - adverse effects
Adult
Antirheumatic Agents - adverse effects
Arthritis
Case studies
Diagnosis
Disease Progression
Drug Eruptions - etiology
Drug Eruptions - pathology
Drug therapy
Female
Health aspects
Humans
Male
Middle Aged
Patient outcomes
Psoriasis
Psoriasis - chemically induced
Psoriasis - pathology
Risk factors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Triggering or worsening of psoriasis has been traditionally reported in patients treated with each of the three currently available tumor necrosis factor (TNF)-α blocking agents (infliximab, etanercept and adalimumab). [2],[4],[5] In a meta-analysis of 13 relevant trials, four of 1332 RA patients who received abatacept as monotherapy as well as 13 of 1945 patients treated with abatacept plus disease-modifying antirheumatic drugs developed psoriasis as an adverse event.
ISSN:0378-6323
0973-3922
1998-3611
DOI:10.4103/0378-6323.125502